Premium
Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS‐CoV‐2
Author(s) -
Cui Yu,
Hu Caixia,
Cheng Yi,
Han Xiaomei,
Wang Wenqing
Publication year - 2022
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.15892
Subject(s) - plasmapheresis , medicine , bullous pemphigoid , covid-19 , pemphigoid , refractory (planetary science) , disease , pandemic , dermatology , intensive care medicine , immunology , virology , antibody , infectious disease (medical specialty) , physics , astrobiology , outbreak
Abstract Bullous pemphigoid (BP) patients were vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection because they have similar risk factors, so we should pay attention to patients with BP during the epidemic of coronavirus disease‐19 (COVID‐19). As far as treatment is concerned, many strategies for BP were changed during the epidemic. Plasmapheresis not only has been included in the guidelines for BP but also has been used successfully to rescue COVID‐19 patients, especially in severe cases. Therefore, it is a feasible choice for BP patients, especially for refractory BP patients, infected with SARS‐CoV‐2. Apart from these, we have reviewed some points for attention during the plasmapheresis session.